Group A Streptococcal Pharyngitis

Group A streptococcal (GAS) pharyngitis is acute inflammation of the pharynx and/or tonsils caused by Streptococcus pyogenes. It is the most common bacterial cause of acute sore throat, concentrated in school-aged children (roughly 5–15 years old) and most active from late autumn through spring, but in every age group most acute pharyngitis is still viral regardless of GAS colonization status.^[1] The central clinical task is therefore not simply recognizing pharyngitis — it is working out whether GAS is actually the cause before reaching for an antibiotic. Untreated or inadequately treated GAS pharyngitis is now understood as a self-limited illness for the great majority of patients; the reason antibiotics are still recommended when GAS is confirmed is prevention of acute rheumatic fever (ARF) and suppurative complications such as peritonsillar abscess, not primarily faster symptom relief, which is at most a modest secondary benefit.^[2]

Typical presentation

• Acute, painful sore throat, usually of abrupt onset.
• Fever.
• Tender, swollen anterior cervical lymph nodes.
• Erythematous pharynx and tonsils, with or without tonsillar exudate.
• A fine, sandpaper-like scarlatiniform rash (scarlet fever) in a minority of patients — a palatal petechiae and "strawberry tongue" may accompany it.
• Headache and abdominal pain (sometimes with vomiting) are common accompanying complaints in children.

Culture-positive GAS pharyngitis with typical tonsillar exudate. (James Heilman, MD, CC BY-SA 3.0, Wikimedia Commons)

No single symptom or exam finding reliably distinguishes GAS from viral pharyngitis — this is precisely why a pretest-probability score plus confirmatory testing is used rather than treating on clinical impression alone (see Assessment & Diagnosis).^[1] The absence of typical viral upper respiratory features is itself a useful clue in favour of GAS: cough, rhinorrhea, hoarseness, conjunctivitis, oral ulcers/stomatitis, a viral exanthem, diarrhea, anosmia, and ageusia all point toward a viral cause instead.

Factors that increase the likelihood the current sore throat is GAS

• Age 5–15 years.
• Close contact with a household member, classmate, or daycare contact with confirmed GAS pharyngitis, or a recognized outbreak setting.
• Late autumn through spring (peak GAS circulation season).
• Crowded living or care settings.

Factors that raise the stakes of a missed or delayed diagnosis (elevated ARF risk)

• A personal history of prior acute rheumatic fever — these patients need antibiotics for essentially any confirmed GAS pharyngitis, since recurrent ARF risk after a further GAS infection is substantially higher than a first episode.
• Indigenous ancestry, or residence in a First Nations, Inuit, or Métis community, reflecting well-documented systemic health-care access inequities that raise contemporary Canadian ARF incidence in these communities relative to the general population.
• Residence in a household or community with a known elevated local ARF incidence, or in a developing-country setting.
• Age 5–15 years is also the peak age range for a first ARF episode, independent of GAS-acquisition risk above.

Differentiating GAS pharyngitis from its common mimics

GAS pharyngitis and infectious mononucleosis frequently coexist — a meaningful proportion of patients with mononucleosis also carry GAS in the oropharynx, so a positive GAS test in a patient with a mononucleosis-like presentation (marked fatigue, splenomegaly, posterior/generalized adenopathy) does not exclude mononucleosis and should not delay appropriate testing for it.

History

• Characterize onset, duration (pharyngitis by definition is acute if under 2 weeks), and associated symptoms — specifically ask about cough, rhinorrhea, conjunctivitis, and diarrhea, since their presence argues for a viral cause.
• Ask about known GAS exposure (household member, classmate, daycare contact) and any personal history of prior acute rheumatic fever.
• Assess ARF-risk context: Indigenous ancestry, community ARF incidence, and recent travel/residence in a higher-incidence setting.
• In a sexually active adolescent or adult, ask specifically about oral-genital contact — gonococcal pharyngitis will not be detected by a standard GAS test and needs its own specific testing.
• Ask about systemic features suggesting a mononucleosis-like illness (marked fatigue, abdominal fullness/splenomegaly) rather than routine bacterial pharyngitis.

Pretest probability: the modified Centor (McIsaac) score

The modified Centor score — commonly called the McIsaac score after the investigator who added the age adjustment to the original Centor criteria — is a simple additive point-sum used to estimate the pretest probability that a patient's sore throat is due to GAS, and to decide who actually needs testing.^[4]

The 2025 IDSA guideline update reinforces using a validated clinical scoring system — the modified Centor/McIsaac score or an equivalent validated tool — specifically to identify low-probability patients (score ≤1) who do not need testing at all, while still recommending testing rather than empiric treatment even at higher scores; a high score raises pretest probability but is not itself a substitute for a positive RADT or culture.^[5] This score has not been validated for children under 3 years old.

Laboratory testing

Adults: a negative RADT (or an initial negative culture) is sufficient to routinely withhold antibiotics, given the low baseline ARF risk in adults. Children and adolescents (or any patient with a high pretest probability): if the RADT is negative, send a confirmatory throat culture and withhold antibiotics for 24-48 hours pending the result — this does not increase ARF risk and avoids unnecessary antibiotic exposure, since antibiotics started within 9 days of symptom onset still prevent ARF.^[1]

• Confirm GAS as the actual cause before initiating antibiotics, rather than treating on symptoms alone.
• Prevent the nonsuppurative complication of greatest concern — acute rheumatic fever — by treating confirmed cases within 9 days of symptom onset.
• Prevent suppurative complications: peritonsillar abscess, acute otitis media, acute sinusitis, cervical lymphadenitis, and — rarely — bacteremia, meningitis, or necrotizing fasciitis.
• Provide symptomatic relief of throat pain and fever.
• Shorten the period of contagiousness and limit transmission to close contacts.
• Avoid unnecessary antibiotic exposure in patients with a low pretest probability of GAS or a low personal risk of ARF.

• Adequate fluid intake, rest, and a soft diet during the acute illness.
• Warm liquids (e.g., tea), cold items (ice chips, popsicles), or throat lozenges/hard candies may give modest symptomatic relief; medicated lozenges, sprays, and gargles are not clearly superior to these simple measures.
• Hand hygiene and respiratory/cough etiquette to limit transmission to household and close contacts.
• A patient started on an appropriate antibiotic is generally considered noncontagious, and safe to return to school, daycare, or work, after roughly 24 hours of treatment and once significantly improved/afebrile — confirm against current local public-health guidance.
• GAS pharyngeal carriers (positive test but no true acute infection) are not treated and pose low transmission and complication risk — routine treatment of chronic carriage is not recommended.

Pregnancy

Diagnosis and testing thresholds are unchanged in pregnancy. Penicillin V, amoxicillin, and cephalosporins (cephalexin, cefadroxil) are all considered safe throughout pregnancy and remain first-line. For a true penicillin allergy in pregnancy, azithromycin or clindamycin can be used.

Breastfeeding

Penicillin V, amoxicillin, cephalosporins, and macrolides (azithromycin, clarithromycin) are all considered compatible with breastfeeding. Clindamycin is also an option; monitor the breastfed infant for possible gastrointestinal effects (diarrhea, candidiasis) from altered infant gut flora.

Pediatrics

GAS pharyngitis and ARF are both genuinely rare under age 3 — testing is generally not indicated in this age group outside a specific atypical presentation or known household exposure. Amoxicillin suspension is frequently preferred over penicillin V suspension for palatability and once-daily/BID dosing convenience. Benzathine penicillin G (see Drug Tables) is a reasonable single-dose IM alternative when oral adherence for a full 10-day course is a genuine concern.

Renal and hepatic impairment

Penicillins and cephalosporins are renally cleared and require dose-interval adjustment in significant renal impairment — confirm against current renal dosing references for the specific agent and degree of impairment. Clindamycin, azithromycin, and clarithromycin do not require routine renal adjustment but clarithromycin needs dose reduction in significant renal impairment specifically; hepatic impairment warrants caution with macrolides given hepatic metabolism.

Asymptomatic GAS carriers

A positive test in an asymptomatic patient (chronic pharyngeal carriage) is not an indication for antibiotic treatment in any population — carriers have low risk of both complications and transmission, and treatment does not reliably eradicate carriage.

Expect noticeable symptomatic improvement within 24–48 hours of starting an appropriate antibiotic; fever typically resolves within this window as well. If there is no improvement by 48–72 hours, reassess rather than simply waiting out the full course (see Treatment Failure). Routine test-of-cure after completing therapy is not needed in an asymptomatic patient who has responded appropriately. For patients in an elevated-ARF-risk group (prior ARF, Indigenous ancestry, high-incidence community), explicitly counsel on the delayed symptoms of rheumatic fever (joint pain/swelling, new murmur or chest symptoms, chorea, subcutaneous nodules, rash) and of poststreptococcal glomerulonephritis (dark urine, swelling, high blood pressure) to watch for over the following 1–5 weeks, since these complications present well after the pharyngitis itself has resolved. During the acute illness, monitor specifically for worsening unilateral throat pain, new trismus, or drooling, which suggest an evolving peritonsillar abscess rather than expected slow improvement.

1. Confirm the full antibiotic course was actually taken at the correct dose, route, and duration — nonadherence is the most common cause of apparent treatment failure.
2. Reconsider whether the original diagnosis was actually confirmed by a positive RADT or culture, or whether treatment was started empirically on symptoms alone; if the latter, retest before assuming drug failure.
3. Consider an alternative or coexisting diagnosis: viral pharyngitis with incidental GAS colonization, infectious mononucleosis, gonococcal pharyngitis in a sexually active patient, or an evolving suppurative complication (peritonsillar abscess) — see the differential table in Assessment & Diagnosis.
4. If GAS relapse is genuinely confirmed after an adequately taken penicillin course, do not switch antibiotic class assuming penicillin resistance — GAS resistance to penicillin has never been documented. Consider incomplete oropharyngeal eradication, a new reinfection from an untreated household contact, or intercurrent viral illness misread as relapse.^[1]
5. For a symptomatic patient with genuinely recurrent, culture-confirmed episodes (multiple discrete episodes rather than persistent carriage with intercurrent viral illnesses), specialist-directed options include clindamycin, amoxicillin-clavulanate, or combined penicillin plus rifampin to address possible copathogens or intracellular GAS reservoirs — these are not routine first-choice regimens.
6. Refer to otolaryngology for consideration of tonsillectomy when recurrent tonsillitis meets a validated frequency threshold: ≥7 episodes in the past year, ≥5 episodes per year for 2 consecutive years, or ≥3 episodes per year for 3 consecutive years, with each episode adequately documented (sore throat plus at least one of fever, tender cervical adenopathy, tonsillar exudate, or a positive GAS test). At least 12 months of watchful observation is reasonable before referral in a patient without other modifying factors; antibiotic allergy/intolerance, PFAPA syndrome, or a history of peritonsillar abscess can justify earlier referral.^[7]

• Diagnosing and treating GAS pharyngitis on symptoms or exam findings alone, without a positive RADT or throat culture.
• Shortening a penicillin or amoxicillin course below 10 days when rheumatic fever prevention is a treatment goal — which it is for nearly every patient being treated.
• Prescribing trimethoprim-sulfamethoxazole, a tetracycline, or a fluoroquinolone for GAS pharyngitis — these do not reliably eradicate GAS from the pharynx regardless of apparent in-vitro susceptibility.
• Treating an asymptomatic GAS carrier or an asymptomatic close contact without symptoms.
• Switching antibiotic class after an apparent treatment failure on the assumption of penicillin resistance, which has never been documented for GAS.
• Defaulting to a macrolide or clindamycin as the routine penicillin-allergy alternative without first establishing whether the prior reaction was actually IgE-mediated — narrow-spectrum cephalosporins are appropriate, preferred, and lower-resistance-risk for most non-severe reactions.
• Missing red-flag features of peritonsillar abscess, epiglottitis, or Lemierre syndrome by treating every sore throat as routine, uncomplicated pharyngitis.
• Relying on a negative RADT alone to exclude infection in a child or adolescent (or any high-ARF-risk patient) instead of sending a confirmatory throat culture.
• Testing or treating a child under 3 years old for routine sore throat without an atypical presentation or known GAS exposure — both GAS pharyngitis and ARF are rare in this age group.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Penicillins (1st line, no penicillin allergy)

No documented GAS resistance to penicillin has ever occurred — these remain preferred over broader-spectrum alternatives.

Cephalosporins (2nd line — non-severe, non-IgE-mediated penicillin allergy)

Avoid this class specifically when the prior penicillin reaction was anaphylaxis, urticaria, or another IgE-mediated pattern given cross-reactivity risk; otherwise a reasonable option after treatment failure with penicillin or in nonimmediate penicillin hypersensitivity.

Lincosamides (severe/IgE-mediated penicillin allergy)

An alternative for true penicillin-allergic patients, and also an option for symptomatic patients with genuinely recurrent, culture-confirmed pharyngitis episodes under specialist direction.

Macrolides (severe/IgE-mediated penicillin allergy)

Alternatives for true penicillin-allergic patients. Macrolide resistance in GAS — unlike penicillin — does occur and varies geographically and over time; these are reserved for genuine allergy rather than used as a routine substitute.

Analgesics and antipyretics

For symptomatic relief in every patient, regardless of whether antibiotics are also indicated — analgesia is not conditional on a positive GAS test.

Adjunctive corticosteroid (special situation only)

Not routinely recommended given the modest benefit magnitude and the confounding effect of concurrent antibiotics on pain relief — reserve for case-by-case use in severe pain after a patient-centred discussion.